PROCARDIA XL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Procardia Xl, and what generic alternatives are available?
Procardia Xl is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in PROCARDIA XL is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the nifedipine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Procardia Xl
A generic version of PROCARDIA XL was approved as nifedipine by ACTAVIS ELIZABETH on January 8th, 1991.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PROCARDIA XL?
- What are the global sales for PROCARDIA XL?
- What is Average Wholesale Price for PROCARDIA XL?
Summary for PROCARDIA XL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 165 |
| Clinical Trials: | 11 |
| Patent Applications: | 3,775 |
| Drug Prices: | Drug price information for PROCARDIA XL |
| DailyMed Link: | PROCARDIA XL at DailyMed |
See drug prices for PROCARDIA XL
Recent Clinical Trials for PROCARDIA XL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Medical College of Wisconsin | N/A |
| Icahn School of Medicine at Mount Sinai | Phase 4 |
| University of Tennessee Medical Center | Early Phase 1 |
Pharmacology for PROCARDIA XL
| Drug Class | Dihydropyridine Calcium Channel Blocker |
| Mechanism of Action | Calcium Channel Antagonists |
US Patents and Regulatory Information for PROCARDIA XL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | PROCARDIA XL | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 019684-001 | Sep 6, 1989 | AB2 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | PROCARDIA XL | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 019684-002 | Sep 6, 1989 | AB2 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | PROCARDIA XL | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 019684-003 | Sep 6, 1989 | AB2 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PROCARDIA XL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | PROCARDIA XL | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 019684-003 | Sep 6, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | PROCARDIA XL | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 019684-003 | Sep 6, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | PROCARDIA XL | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 019684-001 | Sep 6, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | PROCARDIA XL | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 019684-001 | Sep 6, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | PROCARDIA XL | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 019684-001 | Sep 6, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | PROCARDIA XL | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 019684-002 | Sep 6, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | PROCARDIA XL | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 019684-002 | Sep 6, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PROCARDIA XL
See the table below for patents covering PROCARDIA XL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 394944 | ⤷ Sign Up | |
| Denmark | 396381 | ⤷ Sign Up | |
| Netherlands | 192250 | ⤷ Sign Up | |
| Mexico | 9203733 | DISPOSITIVO OSMOTICO PARA ADMINISTRAR CIERTAS DROGAS. | ⤷ Sign Up |
| South Africa | 8106213 | ⤷ Sign Up | |
| Mexico | 9203553 | DISPOSITIVO OSMOTICO CON UN MIEMBRO IMPULSOR DE HIDROGEL. | ⤷ Sign Up |
| Norway | 840248 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
